Clinical Data Data backs GSK’s ovarian cancer blockbuster hopes PharmaphorumGSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme. Clinical DataOncologyRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026